You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

467 Results
Blog post
Jane Smart, Senior Specialist, Technical Training, Legal and Privacy, CCO, shares her unique perspectives of cancer as a patient and as a parent....
Apr 2019
Document
If you got a letter from ColonCancerCheck with an abnormal fecal immunochemical test (FIT) result, the information on this page can help you...
Guidelines and Advice
May 2019
Regimen
Intent: Palliative
Oct 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    letrozole
Oct 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    anastrozole
Oct 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Oct 2025
Document
Document

Pages